SCI Stock Recent News
SCI LATEST HEADLINES
SCI's first-quarter results reflect higher year-over-year revenues and earnings. Also, the gross margin expanded 90 basis points year over year to 27.1%.
The headline numbers for Service Corp. (SCI) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Service Corp. (SCI) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.90 per share. This compares to earnings of $0.89 per share a year ago.
Conference call on Thursday, May 1, 2025, at 8:00 a.m. Central Time.
SCI's Q1 performance is likely to have gained from a resilient business model and favorable demographic trends.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to file for Regulatory Approval of Multikine in Saudi Arabia—Pursuing local partnerships to serve Middle East and North Africa Market.
HOUSTON , April 21, 2025 /PRNewswire/ -- Service Corporation International (NYSE: SCI) announced it expects to issue a press release with financial results for the first quarter 2025 on Wednesday, April 30, 2025. A conference call will be hosted by SCI Management on Thursday, May 1, 2025.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--New study in the scientific journal “Cancer Cell” supports CEL-SCI's strategy to seek early approval for Multikine.
Service Corporation International is well-positioned post-pandemic, benefiting from an aging population and potential corporate tax cuts, with a 'Strong Buy' rating and a fair value of $98 per share. The company experienced significant growth during the pandemic, and despite a recent decline, funeral volumes are expected to normalize, with cemetery revenue showing robust growth. Service Corporation's extensive US network enhances sales productivity and cost optimization, while potential tax cuts could significantly boost net income.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports new data. Treatment with Multikine resulted in up to 95% improvement in Quality of Life for Head and Neck Cancer Patients.